Development of AhR inhibitors for oral antiviral therapy for COVID-19 patients (Q3988868): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in fr: Adding French translations) |
(Changed label, description and/or aliases in de: Adding German translations) |
||
| label / de | label / de | ||
Entwicklung von AhR-Inhibitoren zur oralen antiviralen Therapie für COVID-19-Patienten | |||
Revision as of 20:02, 13 December 2021
Project Q3988868 in Netherlands
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of AhR inhibitors for oral antiviral therapy for COVID-19 patients |
Project Q3988868 in Netherlands |
Statements
399,362.0 Euro
0 references
1,055,117.569 Euro
0 references
37.85 percent
0 references
1 June 2020
0 references
1 June 2021
0 references
Hercules Pharmaceuticals
0 references
53°14'32.42"N, 6°31'47.86"E
0 references
52°10'7.79"N, 4°28'2.14"E
0 references
2333BD
0 references
9747AT
0 references
Identifiers
OP-2014-2023-Noord-OPSNN0302
0 references